Table 1: Clinical Characteristics of the AS patients with Hyperlipidemia.
|
Ho-FH(n=3) |
He-FH(n=3) |
non-FH(n=18) |
p-value(ANOVA test) |
|
|
Age (yrs) at AVR |
31±10 *, ** |
71±11 |
68±11 |
<0.001 |
|
Female (%) |
2 (66.7) |
2 (66.7) |
9 (50) |
NA |
|
AVA (cm2) |
0.9±0.1 |
0.8±0.2 |
1.0±0.6 |
0.821 |
|
peak velocity (m/sec) |
5.4±1.6 |
4.7±1.2 |
4.0±1.0 |
0.147 |
|
Hypertension (%) |
1 (33.3) |
3 (100) |
12 (66.7) |
0.304 |
|
Diabetes mellitus (%) |
0 |
3 (100) |
10 (55.6) |
0.060 |
|
CAD (%) |
3 (100) |
3(100) |
8 (44) |
0.083 |
|
TC (mg/dL) pre-mediation |
734±180 *, ** |
266±58 |
227±45 |
<0.001 |
|
TC (mg/dL) at AVR |
260±28 *, ** |
151±10 |
200±25 |
0.016 |
|
LDL-C (mg/dL) pre-medication |
546 (n=1) |
186±50 |
127±35 |
NA |
|
LDL-C (mg/dL) at AVR |
200±2 *, ** |
94±19 |
123±22 |
0.016 |
AS: aortic stenosis; AVA: aortic valve area, TC: total cholesterol, LDL-C: low-density lipoprotein cholesterol.
*p<0.05 versus He-FH, **p<0.05 versus non-FH, based on the Tukey's HSD (honestly significant difference) test.
“TC and LDL-C pre-medication” showing the data before apheresis and medication in Ho-FH and the data in He- and non-FH at initial diagnosis before induction of statin.